Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Tomaschitz, A; Verheyen, N; Meinitzer, A; Pieske, B; Belyavskiy, E; Brussee, H; Haas, J; März, W; Pieske-Kraigher, E; Verheyen, S; Ofner-Ziegenfuss, L; Hartaigh, BÓ; Schwetz, V; Aberer, F; Grübler, M; Lang, F; Alesutan, I; Voelkl, J; Gaksch, M; Horina, JH; Dimai, HP; Rus-Machan, J; Stiegler, C; Ritz, E; Fahrleitner-Pammer, A; Pilz, S.
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
J Hypertens. 2016; 34(7):1347-1356
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Aberer Felix
Belyavskiy Evgeny
Brussee Helmut
Dimai Hans Peter
Fahrleitner-Pammer Astrid
Gaksch Martin
Grübler Martin Robert
Haas Josef
Horina Jörg
Maerz Winfried
Meinitzer Andreas
Ofner-Ziegenfuss Lisa
Pieske Burkert Mathias
Pilz Stefan
Theiler-Schwetz Verena
Tomaschitz Andreas
Verheyen Nicolas Dominik
Verheyen Sarah

Dimensions Citations:

Plum Analytics:
Accumulating evidence points toward mutual interaction between parathyroid hormone (PTH) and aldosterone as potential mechanism for increasing cardiovascular risk in primary hyperparathyroidism (pHPT). The Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism (EPATH) trial is a single-center, randomized, double-blind, parallel-group, placebo-controlled trial. The primary aim is to evaluate the effects of the mineralocorticoid receptor antagonist eplerenone on plasma intact PTH (iPTH) concentration in patients with pHPT. Secondary end points comprised surrogate parameters of cardiovascular health [24-h ambulatory SBP and DBP and echocardiographic parameters related to systolic/diastolic function as well as to cardiac dimensions]. We enrolled 110 study participants with pHPT, 25-hydroxyvitamin D at least 20 ng/ml and estimated glomerular filtration rate more than 50 ml/min per 1.73 m. Patients were 1 : 1 randomly assigned to receive either 25 mg eplerenone once daily (up-titration after 4 weeks to 50 mg/day) or matching placebo for a treatment period of 8 weeks.The study was completed by 97 participants [mean (SD) age: 67.5 ± 9.5 years; 78.4% women). The mean treatment effect (95% confidence interval) for iPTH was 1.0 (0.9-1.1; P = 0.777) pg/ml. Mean 24-h ambulatory SBP and DBP decreased significantly [mean change (95% confidence interval) -6.3 (-9.4 to -3.3) and -3.7 (-5.7 to -1.7) mmHg, respectively; P < 0.001]. No differences were seen in any further secondary outcomes or frequency of adverse events. In pHPT, treatment with eplerenone compared with placebo had no effect on circulating iPTH levels. Eplerenone treatment was well tolerated and safe and followed by significant decrease of ambulatory blood pressure.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Blood Pressure - drug effects
Blood Pressure Monitoring, Ambulatory -
Diastole -
Double-Blind Method -
Echocardiography -
Female -
Humans -
Hyperparathyroidism, Primary - blood
Hyperparathyroidism, Primary - drug therapy
Hypertension - drug therapy
Male -
Middle Aged -
Mineralocorticoid Receptor Antagonists - adverse effects
Mineralocorticoid Receptor Antagonists - therapeutic use
Parathyroid Hormone - blood
Spironolactone - adverse effects
Spironolactone - analogs & derivatives
Spironolactone - therapeutic use
Systole -
Vitamin D - analogs & derivatives
Vitamin D - blood

Find related publications in this database (Keywords)
blood pressure
parathyroid hormone
randomized clinical trial
© Meduni Graz Impressum